Hyperuricemia in Renal patients: Treat or not to treat

Hyperuricemia management in chronic kidney disease is a challenging task. We encounter this dilemma on regular basis. Kidney disease patients have wide range (CKD population, Hemodialysis & peritoneal dialysis cohort and renal transplant patients). In clinical practice wide range of opinions exists. This dubious area intrigued us to look into it. Looking into available published data majority of studies are observational and few are randomized control trials. All studies favor that high uric acid level has accelerated effect on CKD progression. Controversy is on its management, whether by treating it we are able to slow down CKD progression or not. Data supports that CKD progression is not slowed down but needs more studies to give conclusive answer. In dialysis and renal transplant patients studies showed inverse relationship of high uric levels with all-cause mortality. However, in peritoneal dialysis data suggests linear relationship of hyperuricemia with mortality. A pro as well as anti-oxidant effect of uric acid has been discussed in literature. Variable cut off for hyperuricemia has been used but more census is on 7 mg/dl. Symptomatic gout defi nitely needs uric acid lowering therapy but in asymptomatic hyperuricemia no conclusion so far. There is paucity of data in maintenance dialysis and renal transplant patients. Review article Hyperuricemia in Renal patients: Treat or not to treat Muhammad Tanzeel Abbasi* Muhammad Rashid Asghar, Khuram Bashir and Muhammad Nauman Hashmi Consultant Nephrologist, Department of Nephrology, Multan institute of kidney diseases, Multan, Pakistan Received: 16 July, 2021 Accepted: 05 August, 2021 Published: 06 August, 2021 *Corresponding author: Dr. Muhammad Tanzeel Abbasi, Consultant Nephrologist, Department of Nephrology, Multan institute of kidney diseases, Multan, Pakistan, Tel: 00923336106372; E-mail:


Introduction
Uric acid is a breakdown product of purine metabolism. It was about two centuries ago when uric acid was fi rst identifi ed.
For a long time, hyperuricemia and gout were considered two names of a single entity but with the passage of time, it is quite evident that hyperuricemia has a vast spectrum of metabolic and clinical presentations [1]. It can result either due to overproduction or reduced excretion of uric acid [2]. It is still indecisive that hyperuricemia has a protective or causative role in degenerative disorders of nervous system and renal as well as and cardiovascular illnesses [3]. Hyperuricemia is prevalent worldwide including both developed and underdeveloped countries [4]. Data  Prevalence of hyperuricemia in advanced CKD patients is 60% [5,6]. Hyperuricemia and CKD have a strong correlation but details are still controversial. Previously, monsodium urate crystals were assumed to be a factor in pathogenesis of CKD [7]. However, recent literature highlights a direct involvement of soluble serum urate in pathogenesis and progression of CKD [7,8].
Literature review shows an inverse relationship between high uric acid levels and mortality in End Stage Renal Disease (ESRD) patients undergoing hemodialysis [9]. Low uric acid levels were found to be associated with low all cause and cardiovascular mortality. However, in peritoneal dialysis Citation: Abbasi  patients, few studies have found a direct relationship of hyperuricemia with increased mortality but others have found no signifi cant association [10]. Increased uric acid levels are also frequently observed in early post-transplant period. Although, there is an evidence of inverse association between hyperuricemia with mortality in transplant recipients but it is still inconclusive to establish a benefi cial effect of treating asymptomatic hyperuricemia in this population [11].
There has been much debate about normal levels of uric acid so the defi nition of hyperuricemia is variably presented in literature. Practically, the defi nition of hyperuricemia is based on solubility of uric acid at physiological pH. Some studies have labelled hyperuricemia beyond a cut-off value >7mg/dl in males and >6mg/dl in females [12]. Another study by Desideri G, et al. defi ned uric acid levels above 6mg/dl as hyperuricemia [13]. Physiochemical defi nition of hyperuricemia seems logical and corresponds to uric acid levels beyond 7md/dl. Above this level, uric acid precipitates and may cause symptoms.
This review article is aimed to explore certain unanswered questions about impact of hyperuricemia on progression of CKD including dialysis and transplant patients.

A. Pathophysiological basis of hyperuricemia
Endogenous and exogenous purines are the sources of uric acid. Metabolism of purines mainly occurs in liver but some other tissues (intestines) which have xanthine oxidase enzyme activity, can also metabolize purines [14]. Uric acid is formed as end product of this metabolism. In animals, uric acid is further converted to allantoin by the activity of enzyme uricase [15]. Almost 2/3 rd of the uric acid is excreted by kidneys and remaining 1/3 rd by intestines [ Figure 1]. In kidneys, fi ltration and secretion of uric acid are simultaneously carried out and 90% of the uric acid is ultimately reabsorbed.
Anti-oxidant activity of uric acid plays a fundamental role in tissue healing by initiating infl ammatory cascade. Another basic function of uric acid is to remove nitrogenous wastes from body. Apart from these benefi cial effects, uric acid has been found to be an independent predictor of increased cardiovascular mortality and also causes insulin resistance by increased production of oxygen species [10,16].
Data has analyzed a contributing role of different transporter genes including SLC2A9, SLC22A12, and ABCG2 in hyperuricemia and increased urate excretion. ABCG2 gene was found to be a highest risk factor for gout. Dysfunction of ABCG2 gene has been highlighted as a strong predictor of either under excretion or over excretion of uric acid [17]. Alcohol consumption has remained a topic of discussion due to its association with hypertension. However, it is now surprising to know that increased uric acid level is an independent risk factor of hypertension. A study by Tatsumi Y, et al. is a breakthrough in establishing its role as an independent risk after excluding the effect of alcohol consumption [18].
Uric acid levels are indirectly proportional to decline in renal functions. Decreased excretion of uric acid at the expense of reduced GFR in CKD patients is the main reason of hyperuricemia. Apart from benefi cial effects of anti-oxidant activity, uric acid also has a pro-oxidant effect once it is incorporated into renal cells. The resulting oxidative stress provokes free radical mediated DNA damage and apoptosis [21]. Uric acid upregulates Renin Angiotensin Aldosterone System (RAAS) and resulting endothelial damage due to RAAS activation is another mechanism of decline in GFR [22].  Hyperuricemia is also predominantly involved in infl ammatory damage to renal parenchymal cells. Deposition of monosodium urate crystals has been found to mediate this process [25].

Hyperuricemia and progression of CKD
Hyperuricemia is a modifi able risk factor for CKD and owing

Correlation of CKD stages with uric acid level
Since the mechanism of hyperuricemia also includes  [32]. Uric acid levels above 9mg/dl in patients with serum creatinine of 1.5 mg/dl is high likely to cause urate nephropathy [ Table 1].
A study by Qayyum M, et al. correlated high incidence of hyperuricemia in pre-dialysis CKD population with abnormal metabolic profi le [33]. Although uric acid levels are gradually increased with decline in GFR but this increase is quite rapid in the presence of hyperlipidemia and smoking [34]. The maximum rise of uric acid levels is seen in patients with CKD stage 5 [ Figure 3]. Further conclusive studies will be required to decide cut-off values for uric acid in different stage of CKD.

B. Hyperuricemia in dialysis population
Patients requiring hemodialysis or peritoneal dialysis, both are prone to develop hyperuricemia. Uric acid levels are variably reported in studies to defi ne hyperuricemia in dialysis population. Mean uric acid levels above 7.5mg/ dl in hemodialysis and above 8.5mg/dl in peritoneal dialysis patients are considered abnormal [35,36]. This variability is probably based on prescription of dialysis and timings of sample collection.
In patients with standard hemodialysis prescription, high fl ux dialyzer can remove almost 70% of uric acid and in PD, 15-20ml/min is removed based on peritoneal dialysate fl ow rate [37,38]. In a review article by Murea, et al. 9 out of 14 studies showed an inverse relationship of uric acid levels with all-cause mortality [14]. Rest of fi ve studies found no association. This was a surprising fi nding because it was contrary to pre-dialysis CKD population. The same fi nding has also been reported by Latif, et al. [39]. Different theories have been suggested for this fi nding in HD patients. It was postulated that uric acid is a marker of better nutrition so a low uric acid level can lead to increased mortality. However this opinion was later rejected because mortality was not reduced even after correction of nutritional parameters [40].
Regarding PD patients, only two of these studies found direst relationship of uric acid levels with mortality. This demands further research to document the role of higher uric acid levels in decreasing cardiovascular mortality.
Removal of uric acid in dialysate has a linear relationship with urea. Immediately after dialysis, uric acid levels will be markedly low compared to pre-dialysis levels. Therefore, timings of sample collection is important to explain the effect of dialysis on uric acid levels. Mean uric acid levels will be high between two dialysis sessions. Patients with high predialysis uric acid levels may have normal levels after dialysis which are suffi cient to carry out anti-oxidant activity. This is another explanation of protective effect of hyperuricemia in HD patients [10].

C. Hyperuricemia in kidney transplant recipients
Hyperuricemia is commonly observed in early posttransplant period and can precipitate gout [41]. Cyclosporine has been found to have a signifi cant role in hyperuricemia in transplant recipients. Almost 84% of patients treated with cyclosporine develop hyperuricemia while azathioprine and corticosteroids are responsible in 34% of cases [42]. Other possible causes include use of diuretics, acute tubular necrosis and episodes of graft rejection [43].
Effect of hyperuricemia on renal allograft has not been studied in detail and available data also remains inconclusive in evaluating its association [44]. Some studies have documented an inverse relationship of uric acid levels with graft function while other studies failed to fi nd any association [45,46]. Treatment of hyperuricemia and associated gouty attacks is not free of risks in transplant recipients. So, there is no current recommendation of its treatment and available literature also has confl icting results. However, it is proposed that management of modifi able risk factors including smoking and weight reduction is mandatory and if there is no response, dose reduction or complete avoidance of cyclosporine with suitable alternate option should be adopted [47].

D. Management of hyperuricemia in CKD patients
There is no suffi cient data available to-date about effective role of treating hyperuricemia in chronic kidney disease. Most of the studies including recently published PERL and CKD-FIX trials have clearly documented no impact of lowering UA on CKD progression. However, efforts are routinely carried out to reduce UA levels in view of reducing associated cardiovascular mortality. In such conditions, treatment of hyperuricemia is considered an adjunct strategy in addition to defi nite management of co-morbid conditions [48]. Table 1: Uric acid levels in accordance with serum creatinine in pathogenesis of urate nephropathy.

Medical management
There are three main classes of drugs including xanthine oxidase inhibitors, uricosuric drugs and recombinant uricase for treatment of hyperuricemia.

a. Xanthine oxidase inhibitors
Allopurinol is metabolized to oxypurinol which inhibits Febuxostat is more effective than allopurinol in inhibition of xanthine oxidase. Its excretion is through bile so no dose reduction is required in CKD patients. Focus trial (febuxostat open-label trial of Urate lowering effi cacy and safety) showed a clear benefi t of febuxostat in improving GFR [53]. Another study compared effi cacy of febuxostat vs. allopurinol in 1086 CKD patients. The results of this study were also in favor of febuxostat in terms of GFR improvement [54]. Despite these results, a recent randomized trial by Kimura K, et al. reported no benefi t of febuxostat in improvement of renal functions in CKD patients with asymptomatic hyperuricemia [55]. Some studies have also reported increased mortality associated with febuxostat use in cardiac patients and do not suggest it as fi rst line uric acid lowering therapy [56]. There are very few studies about febuxostat use in dialysis population so US Food and Drug Administration (FDA) has not approved its use in these patients.

b. Uricosuric drugs
Probenecid, sulfi npyrazone and benzbromarone increase uric acid excretion and are very effective as uric acid lowering agents in patients with normal renal functions. However, they are not approved for CKD patients and those with previous history of nephrolithiasis [57]. Sulfi npyrazone has documented interactions with cyclosporine and lowers its trough levels in transplant recipients. So, cyclosporine levels need close monitoring and dose adjustment accordingly.
Benzbromarone is also an effective fi rst line uric acid lowering drug in patients with HLA-B*5801 allele. This allele is more prevalent in Asian population and these patients are prone to allopurinol toxicity [58]. Its use is also limited due to its hepatotoxic effects. Some other drugs including losartan, vitamin C and fenofi brates also have uricosuric properties but their use is confi ned to other systemic conditions [57]. Canakinumab is an interlekin-1 inhibitor and has been approved by European Union for the treatment of hyperuricemia and acute gout in patients with normal renal functions. In CKD and transplant patients, they still have an investigational role and are not approved so far.

c. Recombinant uricase
Pegloticase and rasburicase are recombinant uricase which are recently approved for treatment of symptomatic gout. It converts uric acid to a more soluble product, allantoin. It is given intravenously on alternate weeks in patients who are not responding to oral uric acid lowering medications. It can be given to CKD, dialysis and transplant patients [57]. Rasburicase is also being used in patients receiving cancer chemotherapy who are at risk of tumor lysis syndrome [59].

Conclusion
The relationship of hyperuricemia and decline in renal functions has been established in most of the observational studies. The mechanisms involved in pathogenesis of CKD have also been proposed in literature but there is no conclusive evidence so far. Treatment of symptomatic gout is required with uric acid lowering therapy in CKD patients but there are no current recommendation to treat asymptomatic hyperuricemia in this population. There is paucity of data in patients Citation: Abbasi  Large randomized controlled trials are mandatory to develop a consensus approach in establishing a defi nite mechanism of hyperuricemia in disease progression and effi cacy of its treatment in improving renal functions.